Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types

Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types

ABSTRACT Two multiplex immunoassays are routinely used to assess antibody responses in clinical trials of the 9-valent human papillomavirus (9vHPV) vaccine. The HPV6/11/16/18/31/33/45/52/58 competitive Luminex immunoassay (HPV-9 cLIA) and HPV6/11/16/18/31/33/45/52/58 total immunoglobulin G Luminex i...

Full description

Bibliographic Details
Main Authors:	Katrina M. Nolan, Brent Seaton, Joseph Antonello, Yuhua Zhang, Lauren Cook, Krystyn Delfino, Leonard J. Rubinstein, Kyeongmi Cheon, Thomas Group, Alain Luxembourg, Sheri Dubey
Format:	Article
Language:	English
Published:	American Society for Microbiology 2023-04-01
Series:	mSphere
Subjects:	9-valent human papillomavirus vaccine competitive Luminex immunoassay human papillomavirus immunogenicity total immunoglobulin G immunoassay
Online Access:	https://journals.asm.org/doi/10.1128/msphere.00962-21

Similar Items

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
by: Vu Dinh Thiem, et al.
Published: (2021-07-01)

Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies
by: Anna R. Giuliano, et al.
Published: (2025-12-01)

9-Valent human papillomavirus vaccine: a review of the clinical development program
by: Alain Luxembourg, et al.
Published: (2017-11-01)

Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
by: Sven-Eric Olsson, et al.
Published: (2020-12-01)

Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus
by: Jianhui Nie, et al.
Published: (2016-04-01)

Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women
by: Susanne K. Kjaer, et al.
Published: (2024-12-01)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
by: Suzanne M. Garland, et al.
Published: (2022-11-01)

Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up
by: Susanne K. Kjaer, et al.
Published: (2021-04-01)

Surveillance analysis of adverse events following immunization with the bivalent human papillomavirus vaccine and recombinant human papillomavirus 9-valent vaccine in Hebei province from 2018 to 2022
by: Jinghui WANG, et al.
Published: (2024-09-01)

Human papillomavirus vaccination: An important tool in cervical cancer elimination
by: Veena Pampapati, et al.
Published: (2020-01-01)

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice
by: Lei Bei, et al.
Published: (2024-11-01)

Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
by: Yuan Ding, et al.
Published: (2023-08-01)

Evaluation of human papillomavirus DNA in colorectal cancer and adjacent mucosal tissue samples
by: Luisa Galati, et al.
Published: (2023-11-01)

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
by: Serrano Beatriz, et al.
Published: (2012-12-01)

Human papillomavirus genotypic characteristics of 60,685 subjects under age-expansion vaccination of the nine-valent human papillomavirus vaccine: A cross-sectional study
by: Yu Liu, et al.
Published: (2023-07-01)

Development and evaluation of a bead-based Multiplexed Fluorescent ImmunoAssay (MFIA) for detection of antibodies to Salmonella enterica serogroup B and C1 in pigs
by: Sanne Schou Berger, et al.
Published: (2022-07-01)

Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides
by: Charles Y. Tan, et al.
Published: (2018-08-01)

Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)
by: Paulina N. Naupu, et al.
Published: (2020-12-01)

Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study
by: Kandace L. Amend, et al.
Published: (2022-11-01)

Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials
by: Hilary S. Whitworth, et al.
Published: (2024-08-01)

Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China
by: Mingzhu Li, et al.
Published: (2023-03-01)

Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine: a retrospective real-world study in China
by: Ruogu Meng, et al.
Published: (2023-12-01)

The effect of perceived psychological stress on the immunogenicity of the quadrivalent human papillomavirus vaccine in males
by: Rebecca F. Wu, et al.
Published: (2017-03-01)

A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine
by: Dan Xu, et al.
Published: (2024-11-01)

Molecular Characterization and Developing a Point-of-Need Molecular Test for Diagnosis of Bovine Papillomavirus (BPV) Type 1 in Cattle from Egypt
by: Mohamed El-Tholoth, et al.
Published: (2020-10-01)

Multiplexed suspension array immunoassays for detection of antibodies to pneumococcal polysaccharide and conjugate vaccines
by: Sherry A. Dunbar
Published: (2023-11-01)

Peptide Biomarkers for the Diagnosis of Dengue Infection
by: Francesca Falconi-Agapito, et al.
Published: (2022-01-01)

Resolution of Novel Human Papillomavirus–induced Warts after HPV Vaccination
by: Steffi Silling, et al.
Published: (2014-01-01)

High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study
by: Sarcletti Mario, et al.
Published: (2003-04-01)

In-silico Analysis of Human Papillomavirus – 45 E6, E7 & L1 Proteins as Potential Immunogens
by: Shruthi Padavu, et al.
Published: (2023-03-01)

Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021
by: Fuxing Chen, et al.
Published: (2022-12-01)

Human Papillomavirus-Negative Cervical Cancer: A Comprehensive Review
by: Biyuan Xing, et al.
Published: (2021-02-01)

Systemic 9-valent human papillomavirus vaccine for recalcitrant common cutaneous warts in preparation for renal transplant
by: W. Austin Wyant, MSc, et al.
Published: (2022-04-01)

The papillomaviruses /
by: Garcea, Robert L., et al.
Published: (2007)

Reinfection of Nine-Valent Human Papillomavirus Vaccine Types Among HIV-Negative Men Who Have Sex With Men: A Prospective Cohort Study
by: Lirong Liu, et al.
Published: (2022-07-01)

Development of a multiplex fluorescence immunological assay for the simultaneous detection of antibodies against Cooperia oncophora, Dictyocaulus viviparus and Fasciola hepatica in cattle
by: Sofia N. Karanikola, et al.
Published: (2015-06-01)

The association between high‐risk human papillomavirus and oral lichen planus
by: Maryam Mohammadi, et al.
Published: (2023-02-01)

Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials
by: Chantal Sauvageau, et al.
Published: (2020-03-01)

Human papillomavirus vaccine: An update on recent developments and review of real world data on efficacy
by: Shalini Rajaram, et al.
Published: (2023-01-01)

Features of human papillomavirus infection frequency in different regions of the Russian Federation (literature review)
by: E. V. Belyaeva, et al.
Published: (2018-05-01)